Lunit's Breast Cancer AI Solution 'Insight DBT' Launches Sales in the US... Two Months After FDA Approval

Medical AI company Lunit has launched sales of its 3D breast cancer detection AI solution, 'Lunit Insight DBT,' in the United States. This comes just over two months after receiving approval from the U.S. Food and Drug Administration (FDA) in November last year.

Lunit's 3D Breast Tomosynthesis AI Image Analysis Solution 'Lunit Insight DBT'
[Photo by Lunit]

On the 29th, Lunit announced that it signed a supply contract with Mosaic Breast Imaging (MBI), a breast specialty medical institution in Knoxville, Tennessee, for 'Lunit Insight DBT (Digital Breast Tomosynthesis analysis solution)' and 'Lunit Insight MMG (Mammography analysis solution).' MBI is known for creating a patient-centered diagnostic environment and providing extensive imaging diagnostic services, and it has received perfect scores on Google reviews, reflecting high patient satisfaction.

Through this contract, Lunit will supply MBI with Lunit Insight DBT and Lunit Insight MMG for one year. MBI plans to use these solutions to provide more accurate breast disease diagnoses to patients and improve diagnostic efficiency for medical staff. A Lunit representative stated, "While Lunit Insight MMG and others have already been sold in the U.S., this is the first large-scale contract including Lunit Insight DBT," adding, "We plan to boost U.S. sales by adding Lunit products to the sales network of Volpara Health Technology, which we acquired last month."

David Fosberg, MBI’s Chief Medical Officer and breast imaging specialist, said, “Computer-assisted cancer diagnosis has had limited effectiveness and support in actual clinical settings until now, but recently Lunit has been leading innovation,” and added, “AI-based cancer diagnosis will play a crucial role in detecting more breast cancers and saving more lives from breast cancer.”

Seobum Seok, CEO of Lunit, also said, “It is very encouraging that breast imaging centers in the U.S., where 3D breast cancer screening environments are well developed based on high expertise in medical technology and equipment, have chosen Lunit’s FDA-approved products,” and added, “As the first step for Lunit to enter the U.S. market with Lunit Insight DBT, we plan to focus on expanding our U.S. business and strengthening our sales capabilities this year.”

This content was produced with the assistance of AI translation services.